ClinicalTrials.gg
CompletedNCT00868699Updated Apr 17, 2014Results posted

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

A Phase 3 interventional study of lurasidone and lurasidone in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 55 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
5th of 17
505 · median 348
Started
2009
with 2 others
Phase 3
11 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
8 of 17
Sumitomo Pharma America, Inc.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 5th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 1st registered.

Bipolar Disorder

1,684 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

03

Conditions studied

  • Bipolar Depression

Keywords

  • Bipolar I, Depression
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is diagnosed with bipolar I disorder, most resent episode depressed
  • Subject must have a lifetime history of at least one bipolar manic or mixed episode

Exclusion criteria

Exclusion Criteria:

  • History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
  • Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
  • Imminent risk of suicide or injury to self, others, or property
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    lurasidone low arm

    Drug: lurasidone

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    lurasidone high arm

    Drug: lurasidone

Interventions

  • lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day

  • lurasidone 20 mg/day for Days 1-7

  • DrugPlacebo

    Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

    Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

    Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

    Time frame: Baseline to Week 6

  2. Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

    Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

    Time frame: Baseline to Week 6

07

Results

Posted Jul 2, 2013

Participant flow

4/29/09 to 2/1/12

Participant flow — Overall Study
MilestonePlaceboLurasidone High ArmLurasidone Low Arm
Started170169166
Intent-to-treat population162162161
Safety population168167164
Completed127124123
Not completed434543

Outcome measures

PrimaryMean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
units on a scalePlaceboLurasidone High ArmLurasidone Low Arm
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)-10.7 ± 0.83-15.4 ± 0.83-15.4 ± 0.83
Statistical analysis
  • Placebo vs Lurasidone Low Arm · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -4.6A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.
  • Placebo vs Lurasidone High Arm · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -4.6A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
units on a scalePlaceboLurasidone High ArmLurasidone Low Arm
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)-1.14 ± 0.102-1.71 ± 0.101-1.83 ± 0.102
Statistical analysis
  • Placebo vs Lurasidone Low Arm · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.69A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.
  • Placebo vs Lurasidone High Arm · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.57A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboLurasidone High ArmLurasidone Low Arm
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score-6.3 ± 0.77-9.8 ± 0.73-9.5 ± 0.81
Statistical analysis
  • Placebo vs Lurasidone Low Arm · ANCOVA · p = 0.003 · Mean difference (final values): -3.1A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.
  • Placebo vs Lurasidone High Arm · ANCOVA · p = <0.001 · Mean difference (final values): -3.5A negative difference in least square mean change from baseline between Lurasidone group and placebo indicates a greater improvement in the Lurasidone group over the placebo group.

Adverse events

Collected over April 29,2009 - February 1, 2012. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/168 (0.6%)56/168 (33.3%)
Lurasidone High Arm—5/167 (3%)65/167 (38.9%)
Lurasidone Low Arm—3/164 (1.8%)57/164 (34.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboLurasidone High ArmLurasidone Low Arm
DepressionPsychiatric disorders0/1682/1672/164
Panic AttackPsychiatric disorders0/1681/1671/164
Foot FractureInjury, poisoning and procedural complications0/1681/1670/164
Restless Leg SyndromeInjury, poisoning and procedural complications0/1681/1670/164
HIV InfectionInfections and infestations0/1681/1670/164
Subcutaneous AbscesesInfections and infestations0/1681/1670/164
Duodenal UlcerGastrointestinal disorders1/1680/1670/164
Most frequent other events
Most frequent other events
EventPlaceboLurasidone High ArmLurasidone Low Arm
NauseaGastrointestinal disorders13/16829/16717/164
HeadacheNervous system disorders20/16815/16723/164
AkathisiaNervous system disorders4/16818/16713/164
InsomniaPsychiatric disorders14/16811/1678/164
DizzinessNervous system disorders13/16810/1674/164
SedationNervous system disorders3/16812/1675/164
SomnolenceNervous system disorders7/16811/1677/164

Baseline characteristics

Intent-to-treat population is analyzed.

Age, Categorical
Age, Categorical(Participants)PlaceboLurasidone High ArmLurasidone Low ArmTotal
<=18 years0033
Between 18 and 65 years159159155473
>=65 years3339
Age, Continuous
Age, Continuous(years)PlaceboLurasidone High ArmLurasidone Low ArmTotal
Mean41.2 ± 12.4542.0 ± 12.3541.3 ± 12.3141.5 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLurasidone High ArmLurasidone Low ArmTotal
Female879891276
Male756470209
Region of Enrollment
Region of Enrollment(participants)PlaceboLurasidone High ArmLurasidone Low ArmTotal
France54413
United States587067195
Czech Republic19191755
Ukraine16171649
Romania92415
South Africa18171954
Russian Federation10101131
India27232373
08

Study locations

55 sites
  • Synergy Escondido,710 East Grand Ave.
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3
    Garden Grove, California 92645, United States
  • Excell Research, Inc,3998 Vista Way,Suite 100
    Oceanside, California 92056, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • California Neuropsychopharmacology,CNRI - Los Angeles LLC,8309 Telegraph Road
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacology Clinical Research Institute, LLC,466 26th Street,6th Floor
    San Diego, California 92102, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Florida Clinical Research Center, LLC,3914 State Road 64 East
    Bradenton, Florida 34208, United States
  • Florida Clinical Research Center, LLC,2300 Maitland Center Parkway,Suite 230
    Maitland, Florida 32751, United States
  • Depression and Anxiety Disorders Research Institute
    Tampa, Florida 33613, United States
  • Janus Center for Psychiatric Research,5601 Corporate Way,Suite 103
    West Palm Beach, Florida 33407, United States
  • American Medical Research Inc.,1200 Harger Road Suite 415
    Oak Brook, Illinois 60523, United States
  • Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
    Lake Charles, Louisiana 70601, United States
  • Sheppard Pratt Health System,6501 North Charles Street
    Baltimore, Maryland 21285, United States
  • Albuquerque Neuroscience Inc., 101 Hospital Loop, NE, Suite 209
    Albuquerque, New Mexico 87109, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richard H. Weisler., M.D., P.A., & Associates,700 Spring Forest Road,Suite 125
    Raleigh, North Carolina 27609, United States
  • Mood Disorders Program-UHCMC
    Cleveland, Ohio 44106, United States
  • MetroHealth System
    Cleveland, Ohio 44122, United States
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Clinical Trials, LLC.,4200 Marathon Blvd.,Suite 200
    Austin, Texas 78756, United States
  • Medical Services Prague s.r.o.
    Kolejni 429-5, Praha, Czech Republic
  • Psychiatricka ambulance
    Brno - mesto, 602 00, Czech Republic
  • BIALBI s.r.o., Psychiatricke Oddeleni
    Litomerice, Czech Republic
  • Clintrial, s.r.o.
    Praha, 10 100 00, Czech Republic
  • Hopital Caremeau, Service de Psychiatrie A
    Nimes Cedex, 30 30029, France
  • Zans Ritter, Marcel
    Orvault, 44700, France
  • S V Medical College
    Tirupati, Andh Prad 517507, India
  • Vijayawada Institute of Mental Health and Neurosciences, Psychiatry
    Vijaywada, Andh Prad 520002, India
  • Samvedna Hospitals
    Ahmedabad, Gujarat 380006, India
  • Seth K M School of P G Medicine & Research
    Ahmedabad, Gujarat 380006, India
  • Mental Illness Treatment Rehabilitationi Foundation
    Ahmedabad, Gujarat 380013, India
  • Spandana Nursing Home
    Bangalore, Karna 560010, India
  • Sujata Birla Hospital & Research Centre
    Nashik, Mahara 422101, India
  • R.K. Yadav Memorial Mental Health & De-Addiction Hospital
    Jaipur, Rajasthan 302021, India
  • Manobal Med. Research Centre
    Lucknow, Uttar Prad 226006, India
  • Spitalul Clinic de Urgenta Militar Central
    Bucdresti, 010825, Romania
  • Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca, 400012, Romania
  • Spitalul Clinic de Neuropsihiatrie Craiova
    Craiova, 200620, Romania
  • Spitalul Clinic de Neurologie si Psihiatrie Oradea
    Oradea, 410154, Romania
  • City Psychiatric Hospital #2 of St. Nikolay Chudotvorets
    St. Petersburg, 190121, Russian Federation
  • Bekhterev Scientific Research Psychoneurological Institute
    St. Petersburg, 193019, Russian Federation
  • Psychoneurology Dispensary #4
    St. Petersburg, 197110, Russian Federation
  • Cape Trial Centre
    Cape Town, W. Cape, 7530, South Africa
  • Paarl Medical Centre
    Paarl, W. Cape, 7646, South Africa
  • Clinika
    Port Elizabeth, E. Cape, 6000, South Africa
  • Dey Clinic
    Pretoria, Gauteng, 0181, South Africa
  • Vereeniging Medi-Clinic
    Vereeniging, Free State, 1941, South Africa
  • Chair of Psychiatry and Medical Psychology
    Donetsk, 83008, Ukraine
  • Reg. Psychiatric Hospital
    Odessa, Ukraine
  • Reg Cl.Ps.H.n.a.O.F. Malstev, Fem.Ac. Gen. Ps.D.5B
    Poltava, 36006, Ukraine
  • CRI Cl.Psych.Hosp. #1, Fem. Psych. Dept. #2, Male I
    Simferopol, 95006, Ukraine
  • Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21
    Vinnitsia, 21018, Ukraine
09

References and documents

Publications

  • Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160-8. doi: 10.1176/appi.ajp.2013.13070984. PubMed 24170180 ↗
  • Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun. 2018 Oct;73:717-724. doi: 10.1016/j.bbi.2018.08.009. Epub 2018 Aug 10. PubMed 30102967 ↗
  • Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. J Clin Psychiatry. 2016 Oct;77(10):e1324-e1331. doi: 10.4088/JCP.15m10261. PubMed 27529375 ↗
  • Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y. PubMed 27215976 ↗
  • Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22. PubMed 26730454 ↗
  • Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015 Nov 1;186:376-82. doi: 10.1016/j.jad.2015.07.033. Epub 2015 Aug 5. PubMed 26363720 ↗
  • McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015 Apr;76(4):398-405. doi: 10.4088/JCP.14m09410. PubMed 25844756 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2009
First posted
Mar 25, 2009
Start
Apr 2009
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Jul 2, 2013
Last update
Apr 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00868699
Responsible party
Sponsor
First posted
Mar 25, 2009
Start date
Apr 2009
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Jul 2, 2013
Last update
Apr 17, 2014

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion